Adiponectin Receptor 2 Deficiency Results in Reduced Atherosclerosis in the Brachiocephalic Artery in Apolipoprotein E Deficient Mice

• Anna Lindgren,

  Affiliation Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Malin Levin,

  Affiliation Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

  ⨯
• Sandra Rodrigo Blomqvist,

  Affiliation Discovery Sciences, Transgenics, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Johannes Wikström,

  Affiliation Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Andrea Ahnmark,

  Affiliation Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Christina Mogensen,

  Affiliation Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Gerhard Böttcher,

  Affiliation Global Safety Assessment, Pathology Sciences, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Mohammad Bohlooly-Y,

  Affiliation Discovery Sciences, Transgenics, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Jan Borén,

  Affiliation Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

  ⨯
• Li-Ming Gan,

  Affiliation Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Daniel Lindén

  * E-mail: daniel.linden@astrazeneca.com

  Affiliation Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯